Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2010

View Archived Issues

PAF-R is potential target to treat psoriasis

RAAM-DHF trial finds eplerenone may benefit patients with diastolic heart failure

Lundbeck and Argenta disclose promising preclinical data on MCH1 receptor antagonists

Enoxaparin yields superior net clinical benefit to UFH in subjects undergoing PCI for STEMI

Almirall describes pre-candidate agents for multiple sclerosis

Consistent stability data for Adventrx's ANX-530 to support NDA submission

Abbott responds to FDA advisory committee vote regarding sibutramine

DHEAS levels in plasma identified as putative biomarker for fibromyalgia

Domain Therapeutics describes new adenosine A2A and A3 receptor antagonists

CytoGenix presents preclinical data on DNA vaccine CYDBA-507 for avian flu

Atox Bio doses first participant in phase I AB-103 study

Phase II data reported on STX-209 in autism spectrum disorders

Resverlogix modifies phase II ASSURE trial of RVX-208

SK Holdings presents new inhibitors of MAO-B

Derma Sciences to complete enrollment in phase II trial of DSC-127

TransPharma completes phase Ia ViaDerm-GLP1 agonist trial

Banyu Pharma identifies new inhibitors of wee1-like protein kinase

GSK and Genmab to refocus ofatumumab development program

Immune Targeting Systems begins phase I trial of FP-01

Orexo grants NewBridge rights to market Abstral in Middle East and Africa

Eisai describes new inhibitors of beta-amyloid peptide production

Lonza to manufacture five monoclonal antibodies for GSK under new agreement

Enrollment of first cohort complete in phase I trial of PV-10 for liver cancer

Phase I trial data reported for Pluristem's PLX-PAD in critical limb ischemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...